Iterum Therapeutics Plc Financials

ITRM

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

Financial Health Signals

Piotroski F-Score Weak

1/9

Iterum Therapeutics Plc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

1.08x

For every $1 of reported earnings, Iterum Therapeutics Plc generates $1.08 in operating cash flow (-$26.8M OCF vs -$24.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-5.6x

Iterum Therapeutics Plc earns $-5.6 in operating income for every $1 of interest expense (-$18.7M vs $3.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

This page shows Iterum Therapeutics Plc (ITRM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

N/A

EBITDA

-$18.4M

YoY+59.7%

Iterum Therapeutics Plc's EBITDA was -$18.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 59.7% from the prior year.

Free Cash Flow

-$26.8M

YoY+32.0%

Iterum Therapeutics Plc generated -$26.8M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 32.0% from the prior year.

Net Income

-$24.8M

YoY+35.4%

Iterum Therapeutics Plc reported -$24.8M in net income in fiscal year 2024. This represents an increase of 35.4% from the prior year.

EPS (Diluted)

$-1.26

YoY+57.4%

Iterum Therapeutics Plc earned $-1.26 per diluted share (EPS) in fiscal year 2024. This represents an increase of 57.4% from the prior year.

Cash & Debt

$24.1M

YoY+297.4%

5Y CAGR+38.1%

Iterum Therapeutics Plc held $24.1M in cash against $31.2M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

35M

Iterum Therapeutics Plc had 35M shares outstanding in fiscal year 2024.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$10.5M

YoY-73.8%

5Y CAGR-35.1%

Iterum Therapeutics Plc invested $10.5M in research and development in fiscal year 2024. This represents a decrease of 73.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$2K

YoY-84.6%

5Y CAGR-39.2%

Iterum Therapeutics Plc invested $2K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 84.6% from the prior year.

ITRM Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	$0	$0-100.0%	$37K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$10.5M-73.8%	$40.0M+127.0%	$17.6M+64.5%	$10.7M-49.2%	$21.1M-76.8%	$90.8M
SG&A Expenses	$8.0M+6.8%	$7.5M-41.4%	$12.8M-7.7%	$13.8M+25.1%	$11.1M-2.1%	$11.3M
Operating Income	-$18.7M+60.6%	-$47.5M-56.2%	-$30.4M-23.8%	-$24.5M+23.6%	-$32.1M+68.5%	-$102.0M
Interest Expense	$3.3M+5.1%	$3.1M-0.9%	$3.2M	N/A	N/A	N/A
Income Tax	$240K-60.8%	$613K+103.7%	$301K-57.3%	$705K-5.1%	$743K+67.3%	$444K
Net Income	-$24.8M+35.4%	-$38.4M+13.6%	-$44.4M+51.5%	-$91.6M-76.1%	-$52.0M+49.6%	-$103.1M
EPS (Diluted)	$-1.26+57.4%	$-2.96+18.5%	$-3.63+56.8%	$-8.41+74.1%	$-32.49	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$390K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.3M+26.1%	$1.0M+69.2%	$591K-81.0%	$3.1M+49.7%	$2.1M-47.8%	$4.0M	N/A	$14.9M
SG&A Expenses	$6.5M+55.1%	$4.2M+50.7%	$2.8M+56.0%	$1.8M-6.4%	$1.9M-13.0%	$2.2M	N/A	$1.8M
Operating Income	-$7.7M-39.8%	-$5.5M-49.0%	-$3.7M+24.1%	-$4.9M-22.9%	-$4.0M+35.5%	-$6.2M	N/A	-$16.7M
Interest Expense	$562K+25.2%	$449K-34.5%	$686K-9.3%	$756K+0.8%	$750K+0.1%	$749K	N/A	N/A
Income Tax	$132K+123.7%	$59K-1.7%	$60K-55.9%	$136K+338.7%	$31K-35.4%	$48K	N/A	$161K
Net Income	-$9.0M-37.9%	-$6.5M-33.1%	-$4.9M+19.7%	-$6.1M-22.0%	-$5.0M+29.6%	-$7.1M	N/A	-$3.9M
EPS (Diluted)	$-0.20-25.0%	$-0.16-14.3%	$-0.14+53.3%	$-0.300.0%	$-0.30+34.8%	$-0.46	N/A	$-0.30

ITRM Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$44.6M+69.8%	$26.3M-60.7%	$66.8M-27.0%	$91.5M+179.1%	$32.8M+27.3%	$25.8M
Current Assets	$24.8M-3.2%	$25.6M-59.0%	$62.4M-25.0%	$83.3M+287.8%	$21.5M+83.2%	$11.7M
Cash & Equivalents	$24.1M+297.4%	$6.1M-71.2%	$21.1M-23.2%	$27.4M+89.2%	$14.5M+202.2%	$4.8M
Inventory	$0	$0	$0	$0	$0	$0
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$48.7M+49.0%	$32.7M-15.9%	$38.8M-5.9%	$41.3M-50.5%	$83.4M+60.3%	$52.0M
Current Liabilities	$17.6M+30.2%	$13.5M+49.1%	$9.1M-30.0%	$12.9M-69.0%	$41.7M+12.7%	$37.0M
Long-Term Debt	$31.2M+172.6%	$11.5M+13.5%	$10.1M+45.7%	$6.9M-69.1%	$22.5M+194.6%	$7.6M
Total Equity	-$4.1M+36.3%	-$6.4M-122.9%	$28.0M-44.3%	$50.2M+199.4%	-$50.6M-92.7%	-$26.2M
Retained Earnings	-$486.1M-5.4%	-$461.3M-9.1%	-$422.9M-11.7%	-$378.5M-31.9%	-$286.9M-22.1%	-$234.9M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$32.5M-4.4%	$34.0M+3.2%	$33.0M-26.1%	$44.6M+214.6%	$14.2M-27.8%	$19.6M-25.3%	$26.3M-33.9%	$39.7M
Current Assets	$13.7M-7.8%	$14.9M+10.2%	$13.5M-45.5%	$24.8M+81.0%	$13.7M-28.1%	$19.1M-25.6%	$25.6M-33.6%	$38.5M
Cash & Equivalents	$11.0M-15.5%	$13.0M+3.0%	$12.7M-47.6%	$24.1M+384.8%	$5.0M-32.7%	$7.4M+21.7%	$6.1M+26.1%	$4.8M
Inventory	$1.1M+21.2%	$948K+77.9%	$533K	$0	N/A	N/A	$0	N/A
Accounts Receivable	$448K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$39.9M+5.2%	$37.9M+6.7%	$35.5M-27.0%	$48.7M+94.0%	$25.1M-2.7%	$25.8M-21.1%	$32.7M-10.0%	$36.3M
Current Liabilities	$6.4M+16.2%	$5.5M+52.5%	$3.6M-79.4%	$17.6M+4.9%	$16.8M-5.7%	$17.8M+31.6%	$13.5M-17.6%	$16.4M
Long-Term Debt	$20.0M-0.3%	$20.1M0.0%	$20.1M-35.6%	$31.2M+178.2%	$11.2M0.0%	$11.2M-2.0%	$11.5M-8.1%	$12.5M
Total Equity	-$7.4M-89.9%	-$3.9M-52.2%	-$2.6M+37.4%	-$4.1M+62.6%	-$10.9M-77.4%	-$6.2M+4.0%	-$6.4M-286.6%	$3.4M
Retained Earnings	-$506.5M-1.8%	-$497.5M-1.3%	-$491.0M-1.0%	-$486.1M-2.7%	-$473.4M-1.1%	-$468.4M-1.5%	-$461.3M-2.8%	-$448.9M

ITRM Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$26.8M+31.9%	-$39.3M-112.9%	-$18.5M-16.6%	-$15.8M+70.9%	-$54.5M+33.4%	-$81.9M
Capital Expenditures	$2K-84.6%	$13K-79.0%	$62K+1.6%	$61K+454.5%	$11K-54.2%	$24K
Free Cash Flow	-$26.8M+32.0%	-$39.3M-112.3%	-$18.5M-16.6%	-$15.9M+70.8%	-$54.5M+33.4%	-$81.9M
Investing Cash Flow	$18.2M-22.0%	$23.3M+67.2%	$14.0M+125.6%	-$54.6M-496218.2%	-$11K-100.0%	$40.1M
Financing Cash Flow	$26.7M+2481.3%	$1.0M+156.9%	-$1.8M-102.2%	$83.1M+28.9%	$64.5M+3025.3%	$2.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$7.4M-56.7%	-$4.8M-55.3%	-$3.1M+28.1%	-$4.3M+37.0%	-$6.8M+48.3%	-$13.1M-1.9%	-$12.8M-38.6%	-$9.3M
Capital Expenditures	$12K	$0-100.0%	$2K	$0	N/A	N/A	$0+100.0%	-$3K
Free Cash Flow	-$7.5M-57.0%	-$4.8M-55.2%	-$3.1M+28.1%	-$4.3M	N/A	N/A	-$12.8M-38.6%	-$9.3M
Investing Cash Flow	-$12K	$0+100.0%	-$2K-100.2%	$1.1M-73.8%	$4.2M-41.8%	$7.2M-46.7%	$13.5M+3656.4%	$360K
Financing Cash Flow	$5.4M+6.1%	$5.1M+161.0%	-$8.4M-160.4%	$13.9M+8209.6%	$167K-97.7%	$7.2M+1125.3%	$589K+5790.0%	$10K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ITRM Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	-275732.4%
Net Margin	N/A	N/A	N/A	N/A	N/A	-278729.7%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-55.5%+90.6pp	-146.1%-79.6pp	-66.5%+33.6pp	-100.1%+58.5pp	-158.6%+241.9pp	-400.5%
Current Ratio	1.41-0.5	1.89-5.0	6.89+0.5	6.43+5.9	0.51+0.2	0.32
Debt-to-Equity	-7.65-5.9	-1.79-2.1	0.36+0.2	0.14+0.6	-0.44-0.2	-0.29
FCF Margin	N/A	N/A	N/A	N/A	N/A	-221475.7%

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-1982.3%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-2302.3%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-27.6%-8.5pp	-19.1%-4.3pp	-14.8%+23.4pp	-38.3%-3.0pp	-35.3%+0.9pp	-36.2%	N/A	-9.8%
Current Ratio	2.13-0.6	2.69-1.0	3.72+2.3	1.41+0.6	0.82-0.3	1.07-0.8	1.89-0.5	2.35
Debt-to-Equity	-2.72+2.5	-5.17+2.7	-7.87-0.2	-7.65-6.6	-1.03+0.8	-1.82-0.0	-1.79-5.4	3.63
FCF Margin	-1912.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$4.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

AN2 Therapeutics, Inc. ANTX

$28.8M

OnKure Therapeutics OKUR

$32.7M

Kezar Life Sciences KZR

$46.1M

Tenax Therapeutics Inc TENX

$80.7M

Reviva Pharmaceutcls Hldgs Inc RVPH

$30.0M

Frequently Asked Questions

Is Iterum Therapeutics Plc profitable?

No, Iterum Therapeutics Plc (ITRM) reported a net income of -$24.8M in fiscal year 2024.

What is Iterum Therapeutics Plc's earnings per share (EPS)?

Iterum Therapeutics Plc (ITRM) reported diluted earnings per share of $-1.26 for fiscal year 2024. This represents a 57.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Iterum Therapeutics Plc's EBITDA?

Iterum Therapeutics Plc (ITRM) had EBITDA of -$18.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Iterum Therapeutics Plc have?

As of fiscal year 2024, Iterum Therapeutics Plc (ITRM) had $24.1M in cash and equivalents against $31.2M in long-term debt.

What is Iterum Therapeutics Plc's free cash flow?

Iterum Therapeutics Plc (ITRM) generated -$26.8M in free cash flow during fiscal year 2024. This represents a 32.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Iterum Therapeutics Plc's operating cash flow?

Iterum Therapeutics Plc (ITRM) generated -$26.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Iterum Therapeutics Plc's total assets?

Iterum Therapeutics Plc (ITRM) had $44.6M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Iterum Therapeutics Plc's capital expenditures?

Iterum Therapeutics Plc (ITRM) invested $2K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Iterum Therapeutics Plc spend on research and development?

Iterum Therapeutics Plc (ITRM) invested $10.5M in research and development during fiscal year 2024.

How many shares does Iterum Therapeutics Plc have outstanding?

Iterum Therapeutics Plc (ITRM) had 35M shares outstanding as of fiscal year 2024.

What is Iterum Therapeutics Plc's current ratio?

Iterum Therapeutics Plc (ITRM) had a current ratio of 1.41 as of fiscal year 2024, which is considered adequate.

What is Iterum Therapeutics Plc's debt-to-equity ratio?

Iterum Therapeutics Plc (ITRM) had a debt-to-equity ratio of -7.65 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Iterum Therapeutics Plc's return on assets (ROA)?

Iterum Therapeutics Plc (ITRM) had a return on assets of -55.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Iterum Therapeutics Plc's cash runway?

Based on fiscal year 2024 data, Iterum Therapeutics Plc (ITRM) had $24.1M in cash against an annual operating cash burn of $26.8M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Iterum Therapeutics Plc's debt-to-equity ratio negative or unusual?

Iterum Therapeutics Plc (ITRM) has negative shareholder equity of -$4.1M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Iterum Therapeutics Plc's Piotroski F-Score?

Iterum Therapeutics Plc (ITRM) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Iterum Therapeutics Plc's earnings high quality?

Iterum Therapeutics Plc (ITRM) has an earnings quality ratio of 1.08x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Iterum Therapeutics Plc cover its interest payments?

Iterum Therapeutics Plc (ITRM) has an interest coverage ratio of -5.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.